Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
19,711,628
-
Total 13F shares
-
9,928,243
-
Share change
-
+9,926,022
-
Total reported value
-
$91,849,085
-
Put/Call ratio
-
167%
-
Price per share
-
$9.25
-
Number of holders
-
43
-
Value change
-
+$91,828,085
-
Number of buys
-
42
Institutional Holders of Viracta Therapeutics, Inc. - Common Stock (VIRX) as of Q1 2021
As of 31 Mar 2021,
Viracta Therapeutics, Inc. - Common Stock (VIRX) was held by
43 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
9,928,243 shares.
The largest 10 holders included
BVF INC/IL, CITADEL ADVISORS LLC, Samsara BioCapital, LLC, Sectoral Asset Management Inc, JANUS HENDERSON GROUP PLC, GOLDMAN SACHS GROUP INC, PRICE T ROWE ASSOCIATES INC /MD/, Logos Global Management LP, VANGUARD GROUP INC, and BlackRock Inc..
This page lists
43
institutional shareholders reporting positions in this security
for the Q1 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.